These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 16804830

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.
    Gouw SC, van den Berg HM.
    Semin Thromb Hemost; 2009 Nov; 35(8):723-34. PubMed ID: 20169509
    [Abstract] [Full Text] [Related]

  • 3. Genetic risk factors for inhibitors to factors VIII and IX.
    Oldenburg J, Pavlova A.
    Haemophilia; 2006 Dec; 12 Suppl 6():15-22. PubMed ID: 17123389
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.
    Gouw SC, Van Der Bom JG, Van Den Berg HM, Zewald RA, Ploos Van Amstel JK, Mauser-Bunschoten EP.
    Haemophilia; 2011 Mar; 17(2):275-81. PubMed ID: 21070499
    [Abstract] [Full Text] [Related]

  • 6. Treatment related factors and inhibitor development in children with severe haemophilia A.
    Maclean PS, Richards M, Williams M, Collins P, Liesner R, Keeling DM, Yee T, Will AM, Young D, Chalmers EA, Paediatric Working Party of UKHCDO.
    Haemophilia; 2011 Mar; 17(2):282-7. PubMed ID: 21070501
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A.
    Franchini M, Girelli D, Olivieri O, Castaman G, Lippi G, Poli G, Salvagno GL, Tagariello G, Giuffrida A, de Gironcoli M, Morfini M, Berntorp E, Gandini G.
    Haemophilia; 2006 Jul; 12(4):448-51. PubMed ID: 16834751
    [Abstract] [Full Text] [Related]

  • 10. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A.
    Gouw SC, van den Berg HM, le Cessie S, van der Bom JG.
    J Thromb Haemost; 2007 Jul; 5(7):1383-90. PubMed ID: 17456190
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The need for previously untreated patient population studies in understanding the development of factor VIII inhibitors.
    Gomperts ED.
    Haemophilia; 2006 Nov; 12(6):573-8. PubMed ID: 17083506
    [Abstract] [Full Text] [Related]

  • 13. Intensive peri-operative use of factor VIII and the Arg593-->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A.
    Eckhardt CL, Menke LA, van Ommen CH, van der Lee JH, Geskus RB, Kamphuisen PW, Peters M, Fijnvandraat K.
    J Thromb Haemost; 2009 Jun; 7(6):930-7. PubMed ID: 19548904
    [Abstract] [Full Text] [Related]

  • 14. Risk of inhibitor development in mild haemophilia A increases with age.
    Mauser-Bunschoten EP, Den Uijl IE, Schutgens RE, Roosendaal G, Fischer K.
    Haemophilia; 2012 Mar; 18(2):263-7. PubMed ID: 21851507
    [Abstract] [Full Text] [Related]

  • 15. Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies.
    Coppola A, Santoro C, Tagliaferri A, Franchini M, DI Minno G.
    Haemophilia; 2010 Jan; 16 Suppl 1():13-9. PubMed ID: 20059564
    [Abstract] [Full Text] [Related]

  • 16. Polymorphisms in genes involved in autoimmune disease and the risk of FVIII inhibitor development in Italian patients with haemophilia A.
    Bafunno V, Santacroce R, Chetta M, D'Andrea G, Pisanelli D, Sessa F, Trotta T, Tagariello G, Peyvandi F, Margaglione M.
    Haemophilia; 2010 May; 16(3):469-73. PubMed ID: 20015215
    [Abstract] [Full Text] [Related]

  • 17. Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors.
    d'Oiron R, Volot F, Reynaud J, Peerlinck K, Goudemand J, Guérois C, Rothschild C, Chambost H, Borel-Derlon A, Roussel-Robert V, Marquès-Verdier A, Lienhart A, Berthier AM, Moreau P, Lambert T, MHAI Study Group.
    Semin Hematol; 2006 Jan; 43(1 Suppl 1):S3-9. PubMed ID: 16427382
    [Abstract] [Full Text] [Related]

  • 18. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.
    Astermark J.
    Haemophilia; 2006 Jul; 12 Suppl 3():52-60. PubMed ID: 16683997
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors.
    Astermark J.
    Haemophilia; 2006 Dec; 12 Suppl 6():8-13; discussion 13-4. PubMed ID: 17123388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.